WO2025008464A3 - Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque pour un individu de souffrir d'ascite - Google Patents

Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque pour un individu de souffrir d'ascite Download PDF

Info

Publication number
WO2025008464A3
WO2025008464A3 PCT/EP2024/068881 EP2024068881W WO2025008464A3 WO 2025008464 A3 WO2025008464 A3 WO 2025008464A3 EP 2024068881 W EP2024068881 W EP 2024068881W WO 2025008464 A3 WO2025008464 A3 WO 2025008464A3
Authority
WO
WIPO (PCT)
Prior art keywords
marker
ascites
risk
individual
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2024/068881
Other languages
English (en)
Other versions
WO2025008464A2 (fr
Inventor
Sebastian DE JEL
Frank STÄMMLER
Sebastian RÖTZER
Andrew Robertson
Johannes EIGLSPERGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numares AG
Original Assignee
Numares AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numares AG filed Critical Numares AG
Publication of WO2025008464A2 publication Critical patent/WO2025008464A2/fr
Publication of WO2025008464A3 publication Critical patent/WO2025008464A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne, entre autres, l'utilisation d'un marqueur ou d'un ensemble de marqueurs dans un procédé in vitro pour déterminer le risque pour un individu de souffrir d'ascite. Le marqueur est choisi parmi un premier groupe constitué de lipoprotéine haute densité, d'apolipoprotéine A1, de valine et de pyruvate; l'ensemble de marqueurs comprend au moins deux substances choisies dans un second groupe constitué de lipoprotéine haute densité, d'apolipoprotéine A1, de valine, de pyruvate, de lactate, de myo-inositol et d'anhydrosorbitol.
PCT/EP2024/068881 2023-07-06 2024-07-04 Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque pour un individu de souffrir d'ascite Ceased WO2025008464A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102023117859.8 2023-07-06
DE102023117859 2023-07-06

Publications (2)

Publication Number Publication Date
WO2025008464A2 WO2025008464A2 (fr) 2025-01-09
WO2025008464A3 true WO2025008464A3 (fr) 2025-02-13

Family

ID=91962034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/068881 Ceased WO2025008464A2 (fr) 2023-07-06 2024-07-04 Utilisation d'un marqueur ou d'un ensemble de marqueurs pour déterminer le risque pour un individu de souffrir d'ascite

Country Status (1)

Country Link
WO (1) WO2025008464A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010038014B4 (de) 2010-10-06 2021-10-07 Numares Ag Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung
EP2930515A1 (fr) 2014-04-08 2015-10-14 Universite D'angers Tests de pronostic de troubles hépatiques
US20170370954A1 (en) 2014-11-19 2017-12-28 Metabolon, Inc. Biomarkers for Fatty Liver Disease and Methods Using the Same
CN108990420B (zh) 2016-05-29 2022-06-24 深圳市绘云生物科技有限公司 肝病相关生物标志物和其使用方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABUDEIF AHMED ET AL: "Serum copeptin is associated with major complications of liver cirrhosis and spontaneous bacterial peritonitis", CLINICAL AND EXPERIMENTAL HEPATOLOGY, vol. 9, no. 1, 1 January 2023 (2023-01-01), pages 71 - 78, XP093215233, ISSN: 2392-1099, DOI: 10.5114/ceh.2023.125970 *
GUO QIANG ET AL: "Soluble myeloid triggering receptor expressed on myeloid cell 1 might have more diagnostic value for bacterial ascites than C-reactive protein", OPEN LIFE SCIENCESJUL 8 2022, vol. 13, no. 1, 5 December 2018 (2018-12-05), Open Life SciencesJUL 8 2022, pages 456 - 462, XP093214816, ISSN: 2391-5412, DOI: 10.1515/biol-2018-0054 *
LI WENKUAN: "Urinary Bile Acid Indices as Prognostic Biomarkers for the Urinary Bile Acid Indices as Prognostic Biomarkers for the Complications of Liver Diseases Complications of Liver Diseases", 13 August 2021 (2021-08-13), XP093215177, Retrieved from the Internet <URL:https://digitalcommons.unmc.edu/cgi/viewcontent.cgi?article=1563&context=etd> *
SAMAR MASOUMI-MOGHADDAM ET AL: "Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring", JOURNAL OF OVARIAN RESEARCH, BIOMED CENTRAL LTD, LONDON, UK, vol. 8, no. 1, 19 August 2015 (2015-08-19), pages 58, XP021228235, ISSN: 1757-2215, DOI: 10.1186/S13048-015-0183-X *
SHIGEFUKU RYUTA ET AL: "Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 36, no. 4, 17 September 2020 (2020-09-17), Hoboken, USA, pages 1006 - 1014, XP093215267, ISSN: 0815-9319, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jgh.15215> DOI: 10.1111/jgh.15215 *
ZAMBON S. ET AL: "The lipoprotein composition of plasma and ascitic fluid in liver cirrhosis", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 25, no. 3, 1 March 1995 (1995-03-01), GB, pages 143 - 148, XP093214807, ISSN: 0014-2972, DOI: 10.1111/j.1365-2362.1995.tb01540.x *

Also Published As

Publication number Publication date
WO2025008464A2 (fr) 2025-01-09

Similar Documents

Publication Publication Date Title
Olsson et al. Phosphorus effects on metabolic processes in monoxenic arbuscular mycorrhiza cultures
Shirtliff et al. Farnesol-induced apoptosis in Candida albicans
Kertesz et al. Microbial metabolism of sulfurand phosphorus-containing xenobiotics
Fields et al. Role of nuclear protein kinase C in the mitogenic response to platelet-derived growth factor
Padrón et al. Phosphatidylinositol phosphate 5-kinase Iβ recruits AP-2 to the plasma membrane and regulates rates of constitutive endocytosis
Jia et al. Prognostic implications of micoRNA miR-195 expression in human tongue squamous cell carcinoma
Pöhlmann et al. The Vip1 inositol polyphosphate kinase family regulates polarized growth and modulates the microtubule cytoskeleton in fungi
Martin et al. Identification of PTPσ as an autophagic phosphatase
Ballok et al. Epoxide-mediated differential packaging of Cif and other virulence factors into outer membrane vesicles
Savoldi et al. Farnesol induces the transcriptional accumulation of the Aspergillus nidulans apoptosis‐inducing factor (AIF)‐like mitochondrial oxidoreductase
Guzzon et al. Spoilage potential of brettanomyces bruxellensis strains isolated from Italian wines
Tabe et al. Lysophosphatidylcholine acyltransferase 4 is involved in chondrogenic differentiation of ATDC5 cells
WO2025008464A3 (fr) Utilisation d&#39;un marqueur ou d&#39;un ensemble de marqueurs pour déterminer le risque pour un individu de souffrir d&#39;ascite
El Bissati et al. Toxoplasma gondii arginine methyltransferase 1 (PRMT1) is necessary for centrosome dynamics during tachyzoite cell division
Shwab et al. Calcineurin‐dependent dephosphorylation of the transcription factor CrzA at specific sites controls conidiation, stress tolerance, and virulence of Aspergillus fumigatus
JP2021500912A5 (fr)
Schrey et al. Interaction with mycorrhiza helper bacterium Streptomyces sp. AcH 505 modifies organisation of actin cytoskeleton in the ectomycorrhizal fungus Amanita muscaria (fly agaric)
Liu et al. Resveratrol induces proliferation in preosteoblast cell MC3T3-E1 via GATA-1 activating autophagy
Wu et al. ZDHHC19 localizes to the cell membrane of spermatids and is involved in spermatogenesis
Díaz-Pérez et al. Alteration of fermentative metabolism enhances Mucor circinelloides virulence
Huang et al. Identification of six thiolases and their effects on fatty acid and ergosterol biosynthesis in Aspergillus oryzae
Lee et al. Subcellular localization of aflatoxin biosynthetic enzymes Nor-1, Ver-1, and OmtA in time-dependent fractionated colonies of Aspergillus parasiticus
Bozzo et al. Phosphate or phosphite addition promotes the proteolytic turnover of phosphate‐starvation inducible tomato purple acid phosphatase isozymes
Nguyen et al. Fast-growing Saccharomyces cerevisiae cells with a constitutive unfolded protein response and their potential for lipidic molecule production
FR3129033B1 (fr) Procede de preparation d’une couche mince en materiau ferroelectrique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24745892

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024745892

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024745892

Country of ref document: EP

Effective date: 20260206